Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 4Carcinoma, Ovarian Epithelial 4Uterine Cervical Neoplasms 3Sarcoma 3Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Testicular Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Penile Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Burkitt Lymphoma 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

sapanisertib 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × aflibercept × Gynecologic × Clear all
NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
83 enrolled 21 charts
GastrointestinalGynecologic

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡